How many insider trades does FilingIQ track for TTRX?

FilingIQ tracks 19 Form 4 insider transactions for TTRX (Turn Therapeutics Inc.), covering filings from Oct 8, 2025 onwards. 4 of those were filed in the last 90 days.

Are TTRX insiders net buyers or net sellers?

Across the full Form 4 history for TTRX, 9 transactions (47%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does TTRX insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is TTRX in?

Turn Therapeutics Inc. (TTRX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $98.64M.

TTRX insider trading

Healthcare

Turn Therapeutics Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

47% / 0%

Market cap

$98.64M

About Turn Therapeutics Inc.

Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic resistance through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses. The company was formerly known as Global Health Solutions, Inc and change its name to Turn Therapeutics Inc. in September 2025. Turn Therapeutics Inc. was incorporated in 2015 and is based in Westlake Village, California.

Company website: www.turntherapeutics.com

TTRX insider activity at a glance

FilingIQ has scored 19 insider transactions for TTRX since Oct 8, 2025. The most recent filing in our index is dated Apr 2, 2026.

Across the full history, 9 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on TTRX insider trades is 51.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live TTRX trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for TTRX?: FilingIQ tracks 19 Form 4 insider transactions for TTRX (Turn Therapeutics Inc.), covering filings from Oct 8, 2025 onwards. 4 of those were filed in the last 90 days.
Are TTRX insiders net buyers or net sellers?: Across the full Form 4 history for TTRX, 9 transactions (47%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does TTRX insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is TTRX in?: Turn Therapeutics Inc. (TTRX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $98.64M.

Methodology & sources

Every TTRX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.